Find Cilengitide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 188968-51-6, Emd 121974, Emd-121974, 2-[(2s,5r,8s,11s)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid, Emd-12192, Emd121974
Molecular Formula
C27H40N8O7
Molecular Weight
588.7  g/mol
InChI Key
AMLYAMJWYAIXIA-VWNVYAMZSA-N
FDA UNII
4EDF46E4GI

Cilengitide
Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.
1 2D Structure

Cilengitide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
2.1.2 InChI
InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
2.1.3 InChI Key
AMLYAMJWYAIXIA-VWNVYAMZSA-N
2.1.4 Canonical SMILES
CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
2.1.5 Isomeric SMILES
CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
2.2 Other Identifiers
2.2.1 UNII
4EDF46E4GI
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cyclic-arg-gly-asp-d-phe(n-methyl)val

2. Cyclo(arginyl-glycyl-formylaspartyl-n-methylvalyl)

3. Cyclo(rgdf-n(me)v)

4. Emd 121974

5. Emd121974

2.3.2 Depositor-Supplied Synonyms

1. 188968-51-6

2. Emd 121974

3. Emd-121974

4. 2-[(2s,5r,8s,11s)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic Acid

5. Emd-12192

6. Emd121974

7. Cyclo(l-arginylglycyl-l-alpha-aspartyl-d-phenylalanyl-n-methyl-l-valyl)

8. 4edf46e4gi

9. Chembl429876

10. 2-((2s,5r,8s,11s)-5-benzyl-11-(3-guanidinopropyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic Acid

11. Cyclo(l-arginylglycyl-l-a-aspartyl-d-phenylalanyl-n-methyl-l-valyl)

12. Cilengitide [usan:inn]

13. Unii-4edf46e4gi

14. Cyclo-(arg-gly-asp-dphe-nmeval)

15. Nsc-707544

16. C(rgdfmev)

17. Cyclic-arg-gly-asp-d-phe(n-methyl)val

18. Cilengitide [mi]

19. Cyclo(l-arginylglycyl-l-aspartyl-d-phenylalanyl-n-methyl-l-valyl)

20. Cilengitide [inn]

21. Cilengitide (usan/inn)

22. Cilengitide [usan]

23. Cilengitide [mart.]

24. Cyclo(arginyl-glycyl-formylaspartyl-n-methylvalyl)

25. Schembl34082

26. Cilengitide [who-dd]

27. Gtpl6597

28. Dtxsid9044035

29. Chebi:177833

30. Ex-a1775

31. Zinc3952216

32. Cilengitide Trifluoroacetic Acid Salt

33. Bdbm50235980

34. Nsc774651

35. S6387

36. Akos024257893

37. Cs-1211

38. Cyclo(arg-gly-asp-d-phe-[n-me]val)

39. Db11890

40. Nsc-774651

41. Ncgc00386242-02

42. Ncgc00386242-04

43. Ac-35857

44. As-72195

45. Hy-16141

46. Sw220134-1

47. D03497

48. 968c516

49. A924615

50. Q1091921

51. Cyclo(l-arginylglycyl-l-.alpha.-aspartyl-d-phenylalanyl-n-methyl-l-valyl)

52. [(2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic Acid

53. 2-[(2s,5r,8s,11s)-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-5-(phenylmethyl)-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic Acid

54. 2-[(2s,5r,8s,11s)-5-benzyl-11-(3-carbamimidamidopropyl)-7-methyl-3,6,9,12,15-pentaoxo-8-(propan-2-yl)-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetic Acid

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 588.7 g/mol
Molecular Formula C27H40N8O7
XLogP3-1
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count8
Rotatable Bond Count9
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area238
Heavy Atom Count42
Formal Charge0
Complexity1020
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of high-grade glioma


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty